Structure Therapeutics (GPCR) Operating Leases (2023 - 2026)

Structure Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 37.78% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 37.78% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, up 66.77% from the prior year.
• Operating Leases retreated to $3.2 million in Q1 2026 per GPCR's latest filing, from $3.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.1 million in Q1 2025 and bottomed at $2.2 million in Q4 2024.
• The 4-year median for Operating Leases is $3.5 million (2024), against an average of $3.6 million.
• Across the five-year window, Operating Leases tumbled 46.08% in 2024 and surged 66.77% in 2025, its largest moves.
• Year by year, Operating Leases stood at $4.0 million in 2023, then tumbled by 46.08% to $2.2 million in 2024, then jumped by 66.77% to $3.6 million in 2025, then fell by 11.8% to $3.2 million in 2026.
• Per Business Quant, the three latest GPCR Operating Leases figures stand at $3.2 million (Q1 2026), $3.6 million (Q4 2025), and $4.3 million (Q3 2025).